Pfizer COVID-19 vaccine won't be ready by Election Day
Go Deeper.
Create an account or log in to save stories.
Like this?
Thanks for liking this story! We have added it to a list of your favorite stories.
Pfizer, the apparent front-runner in developing a COVID-19 vaccine for the United States, says its results won't be ready until mid-November at the earliest. That dims any lingering expectation that there could be a vaccine by Election Day, as President Trump has asserted.
Trump's hopes had been bolstered by Pfizer executives, who have said they could have clinical trial results sometime in October. Even if that were so, a pre-election vaccine would mean the Food and Drug Administration would have to give an almost immediate thumbs-up.
Pfizer Chairman and CEO Albert Bourla said in a public statement Friday that it is indeed possible the company could have enough data to know this month whether the vaccine it is developing actually protects people from coronavirus infection. But the company won't have data showing the vaccine is safe before the third week of November at the earliest.
The FDA said earlier this month that, before it reviews a coronavirus vaccine application, a company must have safety data that extends for a median of two months. That means Pfizer needs to wait until half of the volunteers in its ongoing trial have been followed for at least two months before the company can submit its material for FDA review.
Turn Up Your Support
MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all.
"We estimate that we will reach this milestone in the third week of November," Bourla wrote.
The company has been waiting for a certain number of people in its study to come down with COVID-19. Once that threshold has been reached, scientists can analyze the data and see whether those who got sick were in the group that got vaccinated or in the comparison group, which received a dummy shot. The vaccine must reduce the risk of infection by at least 50 percent to be considered for FDA emergency authorization.
Polls show many Americans are hesitant about taking a coronavirus vaccine and concerned that the approval process could be driven by politics. But vaccine companies have said they won't let that happen, and Pfizer said its announcement underscores its commitment to safety.
You can contact NPR science correspondent Richard Harris at rharris@npr.org.
Copyright 2020 NPR. To see more, visit https://www.npr.org.
